骨髓间充质干细胞治疗实验性自身免疫性重症肌无力的实验研究

he purpose of this paper is to investigate the therapeutic efficacy and mechanisms of bone mesenchymal stromal cells (BMSCs) on experimental autoimmune myasthenia gravis (EAMG) both in vivo and in vitro. BMSCs were separated from normal young Lewis rats, and EAMG-model in Lewis rats were established by immunizing R-AChR at the tail root. Intravenous administration of syngenic BMSCs (107/rat) was given to EAMG-model rats on the day of their second immunization. In vitro, AChR-specific T cells were co-cultured with BMSCs at proper ratio, in the presence or absence of 1-MT, the inhibitor of indoleamine 2, 3-dioxygenase (IDO). By the evaluation of clinical score, ELISA and flow cytometry method, the therapeutic effects and the machenisms of BMSCs on EAMG were investigated and found that intravenous administration of syngenic BMSCs effectively ameliorated the pathological features of the disease, and both in vivo and in vitro, the given of BMSCs regulated the imbalance among the Th1, Th2, Th17, and Treg cell subsets, which was at least partially abolished by their secretion of IDO.